Pfizer Guidance Assumes ~$1.1B Revenue Hit From Generic & Biosimilar Competition, No Share Buybacks In 2026
Share
Why It Matters
Pfizer expects to lose about $1.1 billion in sales next year. This tells you the company is being careful with money and saving cash instead of buying back stock.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.